Abstract
Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC)
Journal of clinical oncology, Vol.41(6_suppl), pp.TPS739-TPS739
02/20/2023
DOI: 10.1200/JCO.2023.41.6_suppl.TPS739
Abstract
TPS739 Background: The landscape for treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 7 years with the approvals of tyrosine kinase inhibitors and immune-oncology (IO) agents alone or in combination for untreated mRCC. However, multiple knowledge gaps remain. While active surveillance remains an option for selected pts, prospective evidence on selection of and outcomes for pts is limited. Recent phase III trials all used a common comparator, sunitinib, so no comparative effectiveness data on the new IO-based regimens exists. There are also no routinely used predictive biomarkers in mRCC pt management. Therefore, a better understanding of the biologic determinants associated with cancer heterogeneity and clinical outcomes through blood, tumor, and radiographic based assessments is needed. Importantly, longitudinal changes in health-related quality of life (QOL) and symptom burden of patients with mRCC initiated on new IO–based regimens outside of an interventional clinical trial are poorly understood. Pt reported outcomes (PRO) are rarely captured in a systematic manner. Addressing the evidence gap for how real world pts symptomatically change with treatment combinations and sequences over time is a pressing unmet need. Methods: This is a prospective, observational cohort, phase IV study of 800 mRCC pts in the US. Pts must: be age ≥19 at informed consent; have a diagnosis of mRCC (any histology) with no prior systemic therapy for mRCC (surgery and radiation therapy, prior neoadjuvant/adjuvant therapy for non-mRCC, and pts currently not on systemic therapy and being observed are all permitted); and be able to comply with completion of PROs. Those being treated for active malignancies other than mRCC or not intending to undergo follow up care at a study site within PCORnet are excluded. Pts will undergo consent and baseline assessments, including research blood collection and processing, by the study site team. A novel aspect of this study is the use of PCORnet and Medicare data to minimize data collection burden on sites. PCORnet, the National Patient-Centered Clinical Research Network, is a network of networks that curates EHR data from multiple health systems using a common data model. This allows subsequent follow up to be centrally coordinated by the coordinating center. PRO will be collected at baseline (pre-treatment), every 3 mos for 2 yrs, and then every 6 mos until end of follow up (minimum 18 mos follow-up; maximum 36 mos follow-up). The primary objective is to determine distinct patterns of change in QOL and symptom burden of mRCC pts receiving therapy. Secondary objectives include quantifying the time to treatment discontinuation of pts, identifying patterns of clinical management in the real world setting of mRCC pts on various treatment regimens, and evaluating overall survival of mRCC pts. ClinicalTrials.gov Identifier: NCT04919122 Clinical trial information: NCT04919122 .
Details
- Title: Subtitle
- Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC)
- Creators
- Michael Roger Harrison - Duke UniversityNrupen Anjan Bhavsar - Duke UniversityYasser Ged - Johns Hopkins MedicineAjjai Shivaram Alva - University of Michigan–Ann ArborYousef Zakharia - University of IowaRisa Liang Wong - UPMC Hillman Cancer CenterBrian Addis Costello - Mayo Clinic in ArizonaBenjamin L. Maughan - University of UtahPaul Monk - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteShreya Sinha - Geisinger Wyoming Valley Medical CenterDeepak Kilari - Medical College of WisconsinSarah Jabusch - Duke Clinical Research Insitute, Durham, NCTian Zhang - The University of Texas Southwestern Medical CenterCharles D. Scales - Duke University Health SystemDaniel J. George - Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NCElizabeth Marie Wulff-Burchfield - University of Kansas Medical Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.41(6_suppl), pp.TPS739-TPS739
- DOI
- 10.1200/JCO.2023.41.6_suppl.TPS739
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: Merck, Pfizer, Exelixis, Bristol Myers-Squibb
- Language
- English
- Date published
- 02/20/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984548378202771
Metrics
7 Record Views